Chemomab Therapeutics (CMMB) Cash from Operations Growth (1y) (2018 - 2023)
Chemomab Therapeutics (CMMB) Cash from Operations Growth (1y) (2018 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 158.60% |
| 10 | Chemomab Therapeutics | 714.32 Mn | 703.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 34.82% |
| Sep 30, 2023 | 0.63% |
| Jun 30, 2023 | -31.31% |
| Mar 31, 2023 | -93.64% |
| Dec 31, 2022 | -97.06% |
| Sep 30, 2022 | -103.68% |
| Jun 30, 2022 | -1.68% |
| Mar 31, 2022 | -187.01% |
| Dec 31, 2021 | -86.11% |
| Sep 30, 2021 | -186.35% |
| Jun 30, 2021 | -542.27% |
| Mar 31, 2021 | 32.41% |
| Dec 31, 2020 | 73.71% |
| Sep 30, 2020 | 74.31% |
| Jun 30, 2020 | 77.70% |
| Mar 31, 2020 | 38.73% |
| Dec 31, 2019 | -67.96% |
| Sep 30, 2019 | 47.08% |
| Jun 30, 2019 | -104.01% |
| Mar 31, 2019 | -16.62% |